First human tests begin for vaccine targeting the common cold
NCT ID NCT07399132
Summary
This is an early safety study testing a new vaccine designed to protect against rhinovirus, a main cause of the common cold. Researchers will give the vaccine or a placebo to 144 healthy adults in Australia to check for side effects and see if it triggers an immune response. The study focuses on safety first, with younger and older adults participating in separate groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHINOVIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research
RECRUITINGMelbourne, Australia
Conditions
Explore the condition pages connected to this study.